Close

Roth Capital Affirms Ligand Pharma (LGND) at 'Buy' Following Initiation of LGD-6972 Phase 2 in T2D

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/18/2024

1. LVS
2. TSM
3. SPY
4. NFLX
5. CSX
6. UAL
7. TSLA
8. ALK
9. EFX
10. JWN


Go back to Roth Capital Affirms Ligand Pharma (LGND) at 'Buy' Following Initiation of LGD-6972 Phase 2 in T2D
LIGAND PHARMA (NASDAQ: LGND) Delayed: 72.52 -6.35 (8.05%)
Previous Close $78.87    52 Week High $139.79 
Open $78.70    52 Week Low $82.07 
Day High $78.70    P/E 168.65 
Day Low $72.50    EPS $0.43 
Volume 131,219